Baseline (anti-)infliximab serum trough levels do not predict successful down-titration or cessation of infliximab in Rheumatoid Arthritis patients with long term low disease activity

被引：0
|
作者：
Van der Maas, A. [1 ]
Van den Bemt, B. [2 ]
Van der Hoogen, F. [1 ]
Van Riel, P. [1 ]
Den Broeder, A. [1 ]
机构：
[1] Radboud Univ Nijmegen, Med Ctr, Dept Rheumatol, NL-6525 ED Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Pharm, Sint Maartensklin, NL-6525 ED Nijmegen, Netherlands
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY | 2013年 / 35卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1270 / 1270
页数：1
相关论文
共 34 条
  • [1] CAN BASELINE (ANTI-)INFLIXIMAB SERUM TROUGH LEVELS PREDICT SUCCESSFUL DOWN-TITRATION OR DISCONTINUATION OF INFLIXIMAB IN RHEUMATOID ARTHRITIS PATIENTS WITH LONG TERM LOW DISEASE ACTIVITY?
    Van der Maas, A.
    van den Bemt, B.
    van den Hoogen, F.
    van Riel, P.
    den Broeder, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 220 - 220
  • [2] Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study
    van der Maas, Aatke
    Kievit, Wietske
    van den Bemt, Bart J. F.
    van den Hoogen, Frank H. J.
    van Riel, Piet L.
    den Broeder, Alfons A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (11) : 1849 - 1854
  • [3] Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
    Aatke van der Maas
    Bart JF van den Bemt
    Gertjan Wolbink
    Frank HJ van den Hoogen
    Piet LCM van Riel
    Alfons A den Broeder
    [J]. BMC Musculoskeletal Disorders, 13
  • [4] Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
    van der Maas, Aatke
    van den Bemt, Bart J. F.
    Wolbink, Gertjan
    van den Hoogen, Frank H. J.
    van Riel, Piet L. C. M.
    den Broeder, Alfons A.
    [J]. BMC MUSCULOSKELETAL DISORDERS, 2012, 13
  • [5] SERUM TROUGH LEVELS OF ADALIMUMAB AND INFLIXIMAB INVERSELY CORRELATE WITH DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY ARTHRITIS
    Wong, P.
    Bowling, A.
    Ford, E.
    Freeman, D.
    Bagga, H.
    Langguth, D.
    [J]. INTERNAL MEDICINE JOURNAL, 2017, 47 : 15 - 16
  • [6] Investigating the link between disease activity and infliximab serum levels in rheumatoid arthritis patients
    Valor, L.
    Hernandez-Florez, D.
    de la Torre, I.
    del Rio, T.
    Nieto, J. C.
    Gonzalez, C.
    Lopez-Longo, F. J.
    Monteagudo, I.
    Llinares, F.
    Rosas, J.
    Garrido, J.
    Naredo, E.
    Carreno, L.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (06) : 805 - 811
  • [7] Anti-drug antibodies and low serum trough infliximab levels correlate with disease activity measures in spondyloarthritis patients on an as-needed infliximab treatment
    Patil, Abhishek
    Upadhyaya, Sundeep
    Dawar, Reetika
    Dadhaniya, Nikunjkumar
    Sood, Isha
    Gupta, Sirinder J.
    Handa, Rohini
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2019, 22 (09) : 1638 - 1643
  • [8] Infliximab trough levels and anti-drug antibodies after induction predict long-term clinical remission in infliximab-treated patients with inflammatory bowel disease
    Bodini, G.
    Del Nero, L.
    Giannini, E. G.
    Tolone, S.
    De Bortoli, N.
    Anjali, J.
    Baldissarro, I.
    Savarino, V.
    Savarino, E.
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S408 - S409
  • [9] Successful Dose De-Escalation of Infliximab in Rheumatoid Arthritis Patients with Stable Low Disease Activity and Treatment
    van der Maas, Aatke
    den Broeder, Alfons
    van den Hoogen, Frank H. J.
    Van Riel, Piet
    van den Bemt, Bart J. F.
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S666 - S666
  • [10] Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity
    Verhoef, Lise M.
    van den Bemt, Bart J. F.
    van der Maas, Aatke
    Vriezekolk, Johanna E.
    Hulscher, Marlies E.
    van den Hoogen, Frank H. J.
    Jacobs, Wilco C. H.
    van Herwaarden, Noortje
    den Broeder, Alfons A.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (05):
1234